{"slug":"what-are-peptides-trigeminal","verification":{"valid":true,"entries":1,"head":"6697523c69308267ddcf051e96695a2533e74424c469d41a356a190b9986610a"},"count":1,"models":["grok/grok-4.3"],"yield":{"passes":1,"energy_spent_rows":0,"total_cost_usd":0,"waste_cost_usd":0,"total_tokens":0,"material_outputs":0,"usd_per_output":null,"models":[{"model":"grok/grok-4.3","passes":1,"cost_usd":0,"tokens_total":0,"outputs":0,"waste_passes":0,"usd_per_output":null}],"constraints":{"constitution":"/api/articles/constitution","collaborate_schema":"POST /api/protocol/collaborate","pricing_ppm":{"grok-4.3":[1.25,2.5],"grok/grok-4.3":[1.25,2.5],"grok-build-0.1":[1,2],"kimi/moonshot-v1-8k":[0.15,0.15],"gemini/gemini-2.5-flash":[0.075,0.3],"gemini/gemini-2.0-flash-lite":[0.075,0.3],"openai/gpt-4o":[2.5,10],"openai/gpt-4o-mini":[0.15,0.6],"system/reflex":[0,0],"ingest:deterministic":[0,0],"fill-slots":[0,0]}}},"contributions":[{"seq":0,"id":"k1","ts":"2026-06-29T21:39:46.938Z","model":"grok/grok-4.3","role":"writer","action":"redraft","payload":{"title":"What Are Peptides for Trigeminal","register":"source_ledger","body":"## What's breaking down\nTrigeminal neuralgia involves sudden, severe facial pain from irritation or damage to the trigeminal nerve. Demyelination of nerve fibers, neuroinflammation, and altered pain signaling in the trigeminal ganglion and central pathways often play roles. If myelin sheaths break down faster than they repair, ectopic firing and hypersensitivity can persist. If inflammatory signals like CCL5 stay elevated, they sustain the cycle. Repair-focused peptides are studied mainly in animal models for remyelination and reduced inflammation rather than symptom suppression alone.\n\n## ARA-290\nIf your trigeminal nerve shows signs of small-fiber or demyelinating damage, ARA-290 targets the innate repair receptor to shift from inflammatory to repair signaling. In that case, reduced TRPV1 activity in trigeminal ganglion neurons can follow, lowering pain signal amplification. Human data exist for small-fiber neuropathy but not specifically for trigeminal neuralgia.\n\n## BPC-157\nIf neuroinflammation or nerve integrity loss contributes to your facial pain, BPC-157 is studied for countering oxidative stress and supporting tissue repair in central and peripheral nerves. In that case, improved outcomes in brain injury and nerve models suggest it could address underlying degeneration layers, though direct trigeminal links remain preclinical.\n\n## How these fit together\nARA-290 primarily addresses inflammatory and receptor-level pain pathways in neuropathy models. BPC-157 layers on broader cytoprotective and anti-inflammatory effects seen in CNS injury studies. Together they map to distinct degeneration layers—receptor sensitization versus tissue-level repair—without overlap in the limited data.\n\n## What the evidence actually shows\nA 2025 rat study of DMH1-loaded peptide nanomicelles in trigeminal neuralgia models found restored myelin markers (MBP, MOG) and reduced mechanical hypersensitivity via CCL5 suppression (preclinical). ARA-290 human trials in sarcoidosis-associated small-fiber neuropathy showed improved neuropathic symptoms and quality of life (human). One human trial of erenumab (CGRP antibody) found no reduction in trigeminal neuralgia pain intensity versus placebo (human). BPC-157 shows CNS protective effects in rat traumatic brain injury models but no human trigeminal neuralgia trials (preclinical). A patent describes certain peptide compounds reducing mechanical hypersensitivity in rat infraorbital nerve injury models (preclinical).\n\n## What scientists say\nResearchers note CGRP involvement in trigeminal pathophysiology but emphasize that CGRP blockade does not reliably relieve paroxysmal trigeminal neuralgia pain (human trial data). Preclinical work highlights myelin repair and inflammation control as promising targets beyond current anticonvulsants.\n\n## What people say on Reddit\nUsers in trigeminal neuralgia forums discuss ARA-290 for potential nerve repair benefits in related neuropathies and BPC-157 for possible pain relief, with mixed personal reports and emphasis on consulting physicians (anecdotal).\n\n## What people say on X\nLimited public discussion; occasional mentions of peptide research for facial nerve issues without detailed outcome reports (anecdotal).\n\n## What we do not know\nNo large human randomized trials exist for ARA-290 or BPC-157 specifically in trigeminal neuralgia. Long-term durability of any benefits and optimal protocols remain unestablished. Direct comparisons to standard care are absent.\n\n## Safety and limits\nPeptides discussed here are often used off-label. Human safety data for ARA-290 come from small neuropathy trials showing good tolerability. BPC-157 lacks extensive human safety studies for this use. Always review individual risks with a qualified clinician. Evidence grades remain mostly preclinical or small-scale human for related conditions.","claims":[{"id":"c1","text":"A 2025 rat study found DMH1-loaded peptide nanomicelles restored myelin and reduced pain hypersensitivity in trigeminal neuralgia models via CCL5 suppression.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s1"],"source_status":"sourced","why_material":"Direct preclinical evidence for peptide-based remyelination in TN model.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T21:39:45.491Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"ARA-290 improved neuropathic symptoms in human small-fiber neuropathy trials associated with sarcoidosis.","section":"What the evidence actually shows","tier":"human","source_ids":["s2"],"source_status":"sourced","why_material":"Only human evidence for this peptide in neuropathy.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T21:39:45.491Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"Erenumab did not reduce pain intensity in a human trigeminal neuralgia trial versus placebo.","section":"What the evidence actually shows","tier":"human","source_ids":["s3"],"source_status":"sourced","why_material":"Shows CGRP blockade may not translate to TN relief.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T21:39:45.491Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"BPC-157 shows protective effects in rat models of brain and nerve injury but no human TN trials.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s4"],"source_status":"sourced","why_material":"Limits claims to available data layers.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T21:39:45.491Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12364832/","title":"DMH1-loaded peptide nanomicelles restore myelin and attenuate neuroinflammation in trigeminal neuralgia via CCL5 suppression","quote":"In TN rats, NM@DMH1 significantly attenuated mechanical pain hypersensitivity (p < 0.01 vs model), restored myelin markers (MBP, MOG), and inhibited neuroinflammatory infiltration.","link_status":"ok","quote_status":"unverified"},{"id":"s2","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/24555851/","title":"ARA 290 for treatment of small fiber neuropathy in sarcoidosis","quote":"ARA 290 treatment was consistently associated with a significant improvement of neuropathic pain symptoms in sarcoidosis patients.","link_status":"ok","quote_status":"unverified"},{"id":"s3","type":"pubmed","url":"https://www.sciencedirect.com/science/article/abs/pii/S1474442222002940","title":"Safety and efficacy of erenumab in patients with trigeminal neuralgia","quote":"Erenumab did not reduce pain intensity compared with placebo in patients with trigeminal neuralgia","link_status":"http_400","quote_status":"unverified"},{"id":"s4","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC8504390/","title":"Pentadecapeptide BPC 157 and the central nervous system","quote":"BPC 157 treatment regimens markedly attenuate brain damage induced by traumatic brain injury","link_status":"ok","quote_status":"verified"}]},"rationale":"","tokens_in":0,"tokens_out":0,"cost":0,"prev_hash":"genesis","hash":"6697523c69308267ddcf051e96695a2533e74424c469d41a356a190b9986610a"}]}